8 research outputs found
Dosage de l'EDDP urinaire (métabolite de la méthadone) par une méthode CEDIA
La méthadone est un médicament opiacé largement utilisé
dans le traitement de substitution de la toxicomanie aux
drogues opiacées. En France, la législation impose des
contrôles urinaires réguliers, en particulier la recherche de
la présence de méthadone dans les urines. Le but de ce travail
est d'évaluer l'intérêt du dosage urinaire de l'EDDP
(mĂ©tabolite principal de la mĂ©thadone), comparativement Ă
celui de la méthadone. 462 échantillons urinaires provenant
de 42 patients du centre de dépistage et de prévention des
toxicomanies de l'Hôtel-Dieu de Lyon ont été analysés et les
résultats comparés. L'EDDP a été mesurée avec le réactif
CEDIA® d. a. u.® (Cloned Enzym Immunodonnor Assay) de
Microgenics. Le dosage de la méthadone a été réalisé avec
la trousse Syva Emit® d. a. u.® (Enzyme Multiplied
Immunoassay Technic) de Dade Behring. Les seuils de positivité
étaient respectivement de 100 et 300 µg/l.
436 Ă©chantillons sur 462 soit 94,4 % Ă©taient parfaitement
corrélés. Dans 5,6 % des cas on observait des cas discordants.
Dans 1,3 % des cas nous avons trouvé de la méthadone
et pas d'EDDP. Ces prélèvements correspondaient pour
deux patients Ă une surcharge urinaire frauduleuse par de la
méthadone. Dans 4,3 % des cas nous avons mis en évidence
de l'EDDP mais pas de méthadone. Dans ce cas le pH urinaire
était élevé pour cinq patients.
L'EDDP apparaît donc comme un marqueur plus fiable que
la méthadone dans le suivi des patients sous traitement substitutif
par la méthadone. En effet l'excrétion urinaire de la
méthadone varie en fonction de nombreux paramètres.
L'obtention d'un résultat négatif ne correspond donc pas
forcément à une non-observance du traitement. De plus la
mesure de l'EDDP permet la détection des fraudes par ajout
de méthadone à l'urine
Expériences d’accréditation des électrophorèses sériques et urinaires
International audienc
The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction
International audienceLocal ischemic postconditioning (IPost) and remote ischemic perconditioning (RIPer) are promising cardioprotective therapies in ST-elevation myocardial infarction (STEMI). We aimed: (1) to investigate whether RIPer initiated at the catheterization laboratory would reduce infarct size, as measured using serum creatine kinase-MB isoenzyme (CK-MB) release as a surrogate marker; (2) to assess if the combination of RIPer and IPost would provide an additional reduction. Patients (n = 151) were randomly allocated to one of the following groups: (1) control group, percutaneous transluminal coronary angioplasty (PTCA) alone; (2) RIPer group, PTCA combined with RIPer, consisting of three cycles of 5-min inflation and 5-min deflation of an upper-arm blood-pressure cuff initiated before reperfusion; (3) RIPer+IPost group, PTCA combined with RIPer and IPost, consisting of four cycles of 1-min inflation and 1-min deflation of the angioplasty balloon. The CK-MB area under the curve (AUC) over 72 h was reduced in RIPer, and RIPer+IPost groups, by 31 and 29 %, respectively, compared to the Control group; however, CK-MB AUC differences between the three groups were not statistically significant (p = 0.06). Peak CK-MB, CK-MB AUC to area at risk (AAR) ratio, and peak CK-MB level to AAR ratio were all significantly reduced in the RIPer and RIPer+IPost groups, compared to the Control group. On the contrary, none of these parameters was significantly different between RIPer+IPost and RIPer groups. To conclude, starting RIPer therapy immediately prior to revascularization was shown to reduce infarct size in STEMI patients, yet combining this therapy with an IPost strategy did not lead to further decrease in infarct size
Predictive value of early cardiac magnetic resonance imaging functional and geometric indexes for adverse left ventricular remodelling in patients with anterior ST-segment elevation myocardial infarction: A report from the CIRCUS study
International audienc
Carbon monoxide and prognosis in smokers hospitalised with acute cardiac events: a multicentre, prospective cohort studyResearch in context
Summary: Background: Smoking cigarettes produces carbon monoxide (CO), which can reduce the oxygen-carrying capacity of the blood. We aimed to determine whether elevated expiratory CO levels would be associated with a worse prognosis in smokers presenting with acute cardiac events. Methods: From 7 to 22 April 2021, expiratory CO levels were measured in a prospective registry including all consecutive patients admitted for acute cardiac event in 39 centres throughout France. The primary outcome was 1-year all-cause death. Initial in-hospital major adverse cardiac events (MAE; death, resuscitated cardiac arrest and cardiogenic shock) were also analysed. The study was registered at ClinicalTrials.gov (NCT05063097). Findings: Among 1379 patients (63 ± 15 years, 70% men), 368 (27%) were active smokers. Expiratory CO levels were significantly raised in active smokers compared to non-smokers. A CO level >11 parts per million (ppm) found in 94 (25.5%) smokers was associated with a significant increase in death (14.9% for CO > 11 ppm vs. 2.9% for CO ≤ 11 ppm; p  11 ppm was associated with a significant increase in MAE in smokers during initial hospitalisation after adjustment for comorbidities (odds ratio [OR] 15.75, 95% CI [5.56–44.60]) or parameters of in-hospital severity (OR 10.67, 95% CI [4.06–28.04]). In the overall population, CO > 11 ppm but not smoking was associated with an increased rate of all-cause death (HR 4.03, 95% CI [2.33–6.98] and 1.66 [0.96–2.85] respectively). Interpretation: Elevated CO level is independently associated with a 6-fold increase in 1-year death and 10-fold in-hospital MAE in smokers hospitalized for acute cardiac events. Funding: Grant from Fondation Coeur & Recherche
The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction
Le site de référence du Partenariat européen d’innovation pour un vieillissement actif et en bonne santé MACVIA-LR (contre les maladies chroniques pour un vieillissement en bonne santé en Languedoc-Roussillon)
International audienceLe site de référence du Partenariat européen d'innovation pour un vieillissement actif et en bonne santé MACVIA-LR (contre les maladies chroniques pour un vieillissement en bonne santé en Languedoc-Roussillon